Silverback Therapeutics (SBTX) Competitors

Praxis Precision Medicines (NASDAQ:PRAX) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, community ranking, valuation, institutional ownership, analyst recommendations and media sentiment.

Do institutionals and insiders hold more shares of PRAX or SBTX?

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Does the media prefer PRAX or SBTX?

In the previous week, Praxis Precision Medicines had 5 more articles in the media than Silverback Therapeutics. MarketBeat recorded 5 mentions for Praxis Precision Medicines and 0 mentions for Silverback Therapeutics. Praxis Precision Medicines' average media sentiment score of 0.83 beat Silverback Therapeutics' score of 0.00 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Overall Sentiment
Praxis Precision Medicines	Positive
Silverback Therapeutics	Neutral

Which has higher valuation & earnings, PRAX or SBTX?

Silverback Therapeutics has lower revenue, but higher earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$1.61M	865.01	-$123.28M	-$10.30	-7.23
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	-4.87

Does the MarketBeat Community prefer PRAX or SBTX?

Praxis Precision Medicines received 27 more outperform votes than Silverback Therapeutics when rated by MarketBeat users. Likewise, 73.77% of users gave Praxis Precision Medicines an outperform vote while only 56.25% of users gave Silverback Therapeutics an outperform vote.

Company	Underperform	Outperform
Praxis Precision Medicines	Outperform Votes 45 73.77%	Underperform Votes 16 26.23%
Silverback Therapeutics	Outperform Votes 18 56.25%	Underperform Votes 14 43.75%

Is PRAX or SBTX more profitable?

Silverback Therapeutics has a net margin of 0.00% compared to Praxis Precision Medicines' net margin of -9,409.22%. Silverback Therapeutics' return on equity of -29.62% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	-9,409.22%	-54.86%	-50.52%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Which has more risk & volatility, PRAX or SBTX?

Praxis Precision Medicines has a beta of 2.65, meaning that its share price is 165% more volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.

Do analysts prefer PRAX or SBTX?

Praxis Precision Medicines currently has a consensus price target of $145.20, suggesting a potential upside of 94.93%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts plainly believe Praxis Precision Medicines is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Praxis Precision Medicines beats Silverback Therapeutics on 9 of the 17 factors compared between the two stocks.